ArticleMycopathologia2025
Genotypic and Phenotypic Investigation of Clinical Aspergillus isolates from Iran Indicates Nosocomial Transmission Events of Aspergillus flavus.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aspergillosis: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment.Journal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillosis is one of the most common human fungal infections. The invasive form of this infectious disease has high mortality rates. Moreover, antifungal resistance has been increasing, thereby limiting treatment options. In Iran, limited species distribution, genotyping and susceptibility data regarding aspergillosis is available, especially during the COVID-19 pandemic. In the current study, 124 patients with proven (n = 31), probable (n = 24) and possible (n = 46) aspergillosis and aspergillus colonization (n = 19) were investigated. Isolates were identified to species level based on calmodulin sequencing. Antifungal susceptibility testing was performed with microbroth dilution against common antifungal agents, i.e. amphotericin B, azoles and echinocandins. Additionally, short tandem repeat genotyping was conducted on common Aspergillus species to assess genetic relatedness. Aspergillus flavus was the most common species for proven aspergilossis cases, followed by identification of single cases of A. fumigatus, A. terreus, A. niger. These Aspergillus species were also mostly found in other patients with probably aspergillosis, in addition to four cases of possible aspergillosis with rare or cryptic species A. candidus, A. citrinoterreus, A. tubingensis and A. fumigatiaffinis, respectively. Using available epidemiological cutoff values (ECVs) no isolates were non-wild type to the tested antifungal drugs, while the A. fumigatiaffinis and A. citrinoterreus isolate demonstrated reduced susceptibility to respectively amphotericin B and Itraconazole, and amphotericin B only. With high-resolution short tandem repeat genotyping, several A. flavus clusters were found and their spatial and temporal clustering suggested nosocomial origins. To conclude, aspergillosis cases in Iran were caused by diverse but susceptible species, with A. flavus being dominant and associated with several events of potential nosocomial transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.